Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WXFL 10030390

Next Previous
Drug Profile

WXFL 10030390

Alternative Names: WX 390; WXFL10030390

Latest Information Update: 19 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cisen Pharmaceutical; Shanghai Jiatan Pharmatech
  • Developer Shanghai Jiatan Pharmatech
  • Class Antineoplastics; Pyrimidinones; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Solid tumours
  • No development reported Lymphoma

Most Recent Events

  • 06 Feb 2026 Shanghai Jiatan Pharmatech plans a phase III trial for Cervical cancer (Combination therapy, Recurrent, Metastatic disease, Second-line therapy or greater) (PO) in February 2026 (NCT07392060)
  • 25 Apr 2025 Efficacy and adverse events data from phase Ib/II trial in Cervical cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 13 Sep 2024 Efficacy and adverse events data from a phase II trial in Solid tumors presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top